Home » Stocks » Artelo Biosciences

Artelo Biosciences, Inc. (ARTL)

Stock Price: $1.25 USD 0.04 (3.31%)
Updated Jul 10, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 4.28M
Revenue (ttm) n/a
Net Income (ttm) -3.87M
Shares Out 3.43M
EPS (ttm) -1.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 10, 2020
Last Price $1.25
Previous Close $1.21
Change ($) 0.04
Change (%) 3.31%
Day's Open 1.23
Day's Range 1.21 - 1.30
Day's Volume 81,668
52-Week Range 0.61 - 4.42

More Stats

Market Cap 4.28M
Enterprise Value 2.30M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 3.43M
Float 2.28M
EPS (basic) -1.26
EPS (diluted) -1.31
FCF / Share -1.20
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4,970
Short Ratio 0.02
Short % of Float 0.18%
Beta 1.22
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.17
Revenue n/a
Operating Income -4.60M
Net Income -3.87M
Free Cash Flow -4.11M
Net Cash 1.98M
Net Cash / Share 0.58
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -124.07%
ROE -256.44%
ROIC 627.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$8.00*
Low
8.00
Current: 1.25
High
8.00
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-3.21-2.34-0.23-0.03-0.02-0.02
Net Income-2.17-2.34-0.23-0.03-0.02-0.02
Shares Outstanding2.171.281.461.271.070.51
Earnings Per Share-1.46-1.84-0.18---
Operating Cash Flow-2.79-1.61-0.22-0.02-0.01-0.02
Capital Expenditures------
Free Cash Flow-2.79-1.61-0.22-0.02-0.01-0.02
Cash & Equivalents4.430.340.570.000.020.01
Net Cash / Debt4.430.340.570.000.020.01
Assets6.480.400.57-0.020.01
Liabilities1.020.530.030.02--
Book Value5.46-0.130.54-0.010.020.01
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Artelo Biosciences, Inc.
Country United States
Employees 3
CEO Gregory D. Gorgas

Stock Information

Ticker Symbol ARTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARTL

Description

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system and related signaling pathways. Its product pipeline includes ART27.13, a cannabinoid agonist for the treatment of anorexia associated with cancer; ART12.11, a CBD cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment. It has research and worldwide commercial license agreement with Stony Brook University for FABP5 platform for the development of lead cancer, pain, and inflammation compounds. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is headquartered in La Jolla, California.